

General information about company	
Name of The Company	Syncom Formulations (India) Limited
BSE Scrip Code	524470
NSE Symbol	SYNCOMF
MSE Symbol	
Date of Start of Financial Year	01-04-2022
Date of End of Financial Year	31-03-2023
Reporting Period	Second half yearly
Date of Start of Reporting Period	01-10-2022
Date of End of Reporting Period	31-03-2023
Level of rounding to be used in disclosing related party transactions	Lakhs
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes

(I) We declare that the acceptance of fixed deposits by the banks/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	

Related party transactions														
												Additional details relating to the party/subsidiary		
Sr No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial liability incurred to the listed entity/subsidiary	
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Debt incurred
1	Syncom Formulations (India) Limited		Kedarmal Shankarlal Bankda		Promoter and Whole-time Director	Remuneration		90	approved by members in AGM	33	33	66		
2	Syncom Formulations (India) Limited		Kedarmal Shankarlal Bankda		Promoter and Whole-time Director	Any other transaction	Rent Paid	33	Omnibus Approval taken	10.3	10.29	20.59		
3	Syncom Formulations (India) Limited		Kedarmal Shankarlal Bankda		Promoter and Whole-time Director	Dividend paid		0	approved by members in AGM	34.26	0	34.26		
4	Syncom Formulations (India) Limited		Vijay Shankarlal Bankda		Promoter and Managing Director	Remuneration		90	approved by members in AGM	24	24	48		
5	Syncom Formulations (India) Limited		Vijay Shankarlal Bankda		Promoter and Managing Director	Any other transaction	Rent Paid	5	Omnibus Approval taken	1.3	1.29	2.59		
6	Syncom Formulations (India) Limited		Vijay Shankarlal Bankda		Promoter and Managing Director	Dividend paid		0	approved by members in AGM	29.57	0	29.57		
7	Syncom Formulations (India) Limited		Rinki Ankit Bankda		Whole-time Director	Remuneration		60	approved by members in AGM	14.4	14.4	28.8		
8	Syncom Formulations (India) Limited		Ankit Kedarmal Bankda		Promoter Group and CFO	Remuneration		24	Omnibus Approval taken	12	12	24		
9	Syncom Formulations (India) Limited		Ankit Kedarmal Bankda		Promoter Group and CFO	Dividend paid		0	approved by members in AGM	14.07	0	14.07		
10	Syncom Formulations (India) Limited		Vimla Bankda		Promoter Group	Any other transaction	Rent Paid	30	Omnibus Approval taken	10.3	10.29	20.59		
11	Syncom Formulations (India) Limited		Vimla Bankda		Promoter Group	Remuneration		12	Omnibus Approval taken	4.8	4.8	9.6		
12	Syncom Formulations (India) Limited		Vimla Bankda		Promoter Group	Dividend paid		0	approved by members in AGM	12.02	0	12.02		
13	Syncom Formulations (India) Limited		Asha Vijay Bankda		Promoter Group	Any other transaction	Rent Paid	10	Omnibus Approval taken	2.59	2.59	5.18		
14	Syncom Formulations (India) Limited		Asha Vijay Bankda		Promoter Group	Remuneration		12	Omnibus Approval taken	4.8	4.8	9.6		
15	Syncom Formulations (India) Limited		Asha Vijay Bankda		Promoter Group	Dividend paid		0	approved by members in AGM	13.82	0	13.82		
16	Syncom Formulations		Rahul Bankda		Promoter Group	Any other transaction	Rent Paid	5	Omnibus Approval	1.3	1.29	2.59		

	(India) LimitedSyncom Formulations (India) LimitedSyncom Formulations (India) LimitedSyncom Formulations (India) LimitedSyncom Formulations (India) LimitedSyncom Formulations (India) LimitedSyncom Formulations (India) LimitedSyncom Formulations (India) LimitedSyncom Formulations (India) LimitedSyncom Formulations (India) Limited							taken					
17	Syncom Formulations (India) Limited	Rahul Bankda	Promoter Group	Remuneration		28	Omnibus Approval taken	12	12	24			
18	Syncom Formulations (India) Limited	Rahul Bankda	Promoter Group	Dividend paid		0	approved by members in AGM	0.05	0	0.05			
19	Syncom Formulations (India) Limited	Sulabh Bankda	Promoter Group	Remuneration		10	Omnibus Approval taken	4.2	4.2	8.4			
20	Syncom Formulations (India) Limited	Sulabh Bankda	Promoter Group	Dividend paid		0	approved by members in AGM	2.79	0	2.79			
21	Syncom Formulations (India) Limited	Ankur Bankda	Promoter Group	Remuneration		30	Omnibus Approval taken	12	12	24			
22	Syncom Formulations (India) Limited	Ankur Bankda	Promoter Group	Dividend paid		0	approved by members in AGM	0.02	0	0.02			
23	Syncom Formulations (India) Limited	Payal Bankda	Promoter Group	Remuneration		30	Omnibus Approval taken	12	12	24			
24	Syncom Formulations (India) Limited	Payal Bankda	Promoter Group	Dividend paid		0	approved by members in AGM	3.52	0	3.52			
25	Syncom Formulations (India) Limited	Synmex Pharma Private Limited	Wholly-Owned Subsidiary	Any other transaction	Rent Received	2	Omnibus Approval taken	0.35	0	0.35			
26	Syncom Formulations (India) Limited	Synmex Pharma Private Limited	Wholly-Owned Subsidiary	Sale of goods or services		200	Omnibus Approval taken	79.46	0	79.46			
27	Syncom Formulations (India) Limited	Synmex Pharma Private Limited	Wholly-Owned Subsidiary	Investment		1	Omnibus Approval taken	0	1	1			
28	Syncom Formulations (India) Limited	Vincit Biotech International Private Limited	Wholly-Owned Subsidiary	Any other transaction	Rent Received	2	Omnibus Approval taken	0.35	0	0.35			
29	Syncom Formulations (India) Limited	Vincit Biotech International Private Limited	Wholly-Owned Subsidiary	Sale of goods or services		2	Omnibus Approval taken	0.03	0	0.03			
30	Syncom Formulations (India) Limited	Vincit Biotech International Private Limited	Wholly-Owned Subsidiary	Investment		1	Omnibus Approval taken	0	1	1			
31	Syncom Formulations (India) Limited	Sante Biotech Private Limited	Wholly-Owned Subsidiary	Any other transaction	Rent Received	2	Omnibus Approval taken	0.35	0	0.35			
32	Syncom Formulations (India) Limited	Sante Biotech Private Limited	Wholly-Owned Subsidiary	Investment		1	Omnibus Approval taken	0	1	1			
33	Syncom Formulations	Prachi Jain	Company Secretary	Remuneration		4	Omnibus Approval	1.69	1.69	3.38			

	(India) Limited							taken					
34	Syncom Formulations (India) Limited		Synmex pharma		Promoters are Partner	Sale of goods or services		3000	approved by members in AGM	425.9	464.96	890.86	
35	Syncom Formulations (India) Limited		Vincit International		Promoters are Partner	Sale of goods or services		3000	approved by members in AGM	1064.46	579.46	1643.92	
36	Syncom Formulations (India) Limited		KEDARMAL BANKDA HUF		Promoter Group	Dividend paid		0	approved by members in AGM	3.15	0	3.15	
37	Syncom Formulations (India) Limited		VIJAY BANKDA HUF		Promoter Group	Dividend paid		0	approved by members in AGM	3.62	0	3.62	
38	Syncom Formulations (India) Limited		SHANDARLAL BANKDA HUF		Promoter Group	Dividend paid		0	approved by members in AGM	0.82	0	0.82	
39	Syncom Formulations (India) Limited		Strand Developers Pvt Ltd		Promoter Group	Dividend paid		0	approved by members in AGM	10.76	0	10.76	
40	Syncom Formulations (India) Limited		Paradise Vyapaar Pvt Ltd		Promoter Group	Dividend paid		0	approved by members in AGM	14.16	0	14.16	
41	Syncom Formulations (India) Limited		KRISHNA DAS NEEMA		Independent Director	Any other transaction	Sitting Fees	0	not applicable	0.05	0.2	0.25	
42	Syncom Formulations (India) Limited		PRAVEEN JINDAL		Independent Director	Any other transaction	Sitting Fees	0	not applicable	0.05	0.1	0.15	
43	Syncom Formulations (India) Limited		RUCHI JINDAL		Independent Director	Any other transaction	Sitting Fees	0	not applicable	0.05	0	0.05	
44	Syncom Formulations (India) Limited		VINOD KABRA		Independent Director	Any other transaction	Sitting Fees	0	not applicable	0.05	0.2	0.25	
Total value of transaction during the reporting period										1874.41			

